Recursion Pharmaceuticals is trading at $3.58, up 10.00%, supported primarily by broad biotech-sector strength rather than a fresh company-specific announcement.
- XBI is up 2.06%, providing a sector-wide tailwind
- No new company-specific announcement was identified on August 25, 2026
- The latest major update was second-quarter results released August 5, 2026